WHO pauses Quebec's plant-based COVID-19 vaccine approval

Mar 17 2022, 2:16 pm

The World Health Organization (WHO) says Quebec’s plant-based COVID-19 vaccine will “very likely” not be approved for emergency use.

Despite the new vaccine’s approval in Canada, the WHO cites the company’s link to the tobacco industry as the reason for pausing the vaccine approval.

In February, Health Canada approved Quebec-based organization Medicago’s plant-based COVID-19 vaccine. The treatment would be a “world-first.”

The Canadian government bought over 70 million doses of the vaccine, with room for 56 million more come October. The Medicago vaccine goes by the colloquial name “Covifenz” and is administered in two shots. It was the sixth vaccine to be approved in the country.

The WHO has paused the application for the pre-qualification approval, specifically citing Medicago’s ties to cigarette company Philip Morris International.

“Due to its connections — it’s partially owned by Philip Morris — so the process is put on hold,” said Mariangela Simao, WHO’s assistant director-general for drug access, vaccines and pharmaceuticals, at a media briefing on Wednesday. “It’s well known the WHO and the UN have a very strict policy regarding engagement with the tobacco and arms industry, so the process is put on hold. It’s very likely it won’t be accepted for emergency use listing.”

 

View this post on Instagram

 

A post shared by Medicago (@medicagoinc)

The WHO website’s listing of emergency use vaccines says the Medicago shots are “not accepted.” As of now, Canada is the only country to have approved the plant-based vaccine.

Clinical trials had shown that the Medicago vaccine was up to 75% effective against symptomatic infection and 100% effective against COVID-19 “severe diseases.”

Across Canada, Medicago was hailed as being the solution for people who were hesitant to take a vaccine that was mRNA based, like Pfizer-BioNTech and Moderna.

Ty JadahTy Jadah

+ News
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT